AR046454A1 - Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceutica - Google Patents
Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceuticaInfo
- Publication number
- AR046454A1 AR046454A1 ARP040104208A ARP040104208A AR046454A1 AR 046454 A1 AR046454 A1 AR 046454A1 AR P040104208 A ARP040104208 A AR P040104208A AR P040104208 A ARP040104208 A AR P040104208A AR 046454 A1 AR046454 A1 AR 046454A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- disorder
- benzazepin
- disease
- treatment
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- -1 BENZAZEPIN-N-ACETIC ACID COMPOUND Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 3
- 230000008085 renal dysfunction Effects 0.000 abstract 3
- 238000011282 treatment Methods 0.000 abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- NTQSYIWTDXTRGG-UHFFFAOYSA-N 2-(1-benzazepin-1-yl)acetic acid Chemical class OC(=O)CN1C=CC=CC2=CC=CC=C12 NTQSYIWTDXTRGG-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000003345 hyperglycaemic effect Effects 0.000 abstract 1
- 230000001631 hypertensive effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de derivados de ácido benzazepin-N-acético que contienen un grupo oxo en la posición a con relación al átomo de nitrógeno y están sustituidos en la posición 3 con un radical 1-(carboxialquil)ciclopentilcarbonilamino, y/o sus sales y ésteres biolabiles y/o solvatos fisiológicamente aceptables de los mismos para la manufactura de una composición farmacéutica para el tratamiento y/o profilaxis de disfunción, enfermedad o trastorno renal en mamíferos superiores y particularmente en seres humanos, preferiblemente pacientes humanos que padecen de diabetes. Producción de composiciones farmacéuticas y productos adecuados para el tratamiento. Tratamiento y/o profilaxis de disfunción, enfermedad o trastorno renal, preferiblemente en pacientes diabéticos pero en un sentido más amplio también en pacientes con síndrome X o en particular en pacientes con una disfunción, enfermedad y/o trastorno renal que además son hipertensos, obesos, hiperglicémicos y/o sujetos a trastornos metabólicos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03104264 | 2003-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046454A1 true AR046454A1 (es) | 2005-12-07 |
Family
ID=34610099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104208A AR046454A1 (es) | 2003-11-18 | 2004-11-15 | Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceutica |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7273860B2 (es) |
| EP (1) | EP1687006B1 (es) |
| JP (1) | JP4824573B2 (es) |
| CN (1) | CN100566719C (es) |
| AR (1) | AR046454A1 (es) |
| AT (1) | ATE378053T1 (es) |
| AU (1) | AU2004290925B2 (es) |
| BR (1) | BRPI0416706A (es) |
| CA (1) | CA2545802A1 (es) |
| DE (1) | DE602004010172T2 (es) |
| ES (1) | ES2297536T3 (es) |
| MX (1) | MXPA06005547A (es) |
| PL (1) | PL1687006T3 (es) |
| TW (1) | TWI344366B (es) |
| WO (1) | WO2005049035A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE406438T1 (de) * | 1999-11-19 | 2008-09-15 | Solvay Pharm Bv | Menschliches homolog aus der familie der metalloproteasen |
| PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| US20060159748A1 (en) * | 2004-12-23 | 2006-07-20 | Rajesh Jain | Oral immediate release formulation of a poorly water-soluble active substance |
| JP7228529B2 (ja) * | 2017-12-11 | 2023-02-24 | 株式会社アエタスファルマ | １，４－ベンゾチアゼピン－１－オキシド誘導体の光学異性体を含む腎機能障害の改善薬 |
| PL424453A1 (pl) | 2018-01-31 | 2019-08-12 | Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością | Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) |
| KR102494613B1 (ko) * | 2018-06-22 | 2023-02-06 | 신액트 파마 에이피에스 | 단백뇨의 치료 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0254032A3 (en) * | 1986-06-20 | 1990-09-05 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| DE19510566A1 (de) * | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19638020A1 (de) * | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
| DE19906310A1 (de) * | 1999-02-16 | 2000-08-17 | Solvay Pharm Gmbh | Arzneimittel zur Behandlung von Bluthochdruck |
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| MXPA04006887A (es) * | 2002-01-16 | 2004-12-06 | Solvay Pharm Bv | Sales solidas de compuestos de benzazepina y su uso en la preparacion de compuestos farmaceuticos. |
| PE20040468A1 (es) * | 2002-05-17 | 2004-09-14 | Novartis Ag | Combinacion de compuestos organicos |
-
2004
- 2004-11-15 EP EP04818828A patent/EP1687006B1/en not_active Expired - Lifetime
- 2004-11-15 BR BRPI0416706-6A patent/BRPI0416706A/pt not_active IP Right Cessation
- 2004-11-15 TW TW093134862A patent/TWI344366B/zh not_active IP Right Cessation
- 2004-11-15 WO PCT/EP2004/052963 patent/WO2005049035A1/en not_active Ceased
- 2004-11-15 JP JP2006540446A patent/JP4824573B2/ja not_active Expired - Fee Related
- 2004-11-15 AR ARP040104208A patent/AR046454A1/es not_active Application Discontinuation
- 2004-11-15 CA CA002545802A patent/CA2545802A1/en not_active Abandoned
- 2004-11-15 AU AU2004290925A patent/AU2004290925B2/en not_active Ceased
- 2004-11-15 DE DE602004010172T patent/DE602004010172T2/de not_active Expired - Lifetime
- 2004-11-15 MX MXPA06005547A patent/MXPA06005547A/es active IP Right Grant
- 2004-11-15 ES ES04818828T patent/ES2297536T3/es not_active Expired - Lifetime
- 2004-11-15 CN CNB2004800330307A patent/CN100566719C/zh not_active Expired - Fee Related
- 2004-11-15 AT AT04818828T patent/ATE378053T1/de not_active IP Right Cessation
- 2004-11-15 PL PL04818828T patent/PL1687006T3/pl unknown
- 2004-11-16 US US10/988,847 patent/US7273860B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1878557A (zh) | 2006-12-13 |
| AU2004290925B2 (en) | 2010-07-01 |
| AU2004290925A1 (en) | 2005-06-02 |
| ATE378053T1 (de) | 2007-11-15 |
| TWI344366B (en) | 2011-07-01 |
| US7273860B2 (en) | 2007-09-25 |
| EP1687006B1 (en) | 2007-11-14 |
| HK1097762A1 (zh) | 2007-07-06 |
| PL1687006T3 (pl) | 2008-01-31 |
| JP2007511582A (ja) | 2007-05-10 |
| CN100566719C (zh) | 2009-12-09 |
| WO2005049035A1 (en) | 2005-06-02 |
| CA2545802A1 (en) | 2005-06-02 |
| BRPI0416706A (pt) | 2007-01-16 |
| MXPA06005547A (es) | 2006-08-17 |
| DE602004010172D1 (de) | 2007-12-27 |
| ES2297536T3 (es) | 2008-05-01 |
| TW200526228A (en) | 2005-08-16 |
| US20050137183A1 (en) | 2005-06-23 |
| EP1687006A1 (en) | 2006-08-09 |
| DE602004010172T2 (de) | 2008-09-11 |
| JP4824573B2 (ja) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27913A1 (es) | Forma de dosificacion una vez al dia de pramipexol | |
| CY1106784T1 (el) | Υποκατεστημενα παραγωγα φαινυλ προπιονικου οξεος ως συναγωνιστες του ανθρωπινου υπεροξυσωματικου πολλαπλασιαστη - ενεργοποιημενου υποδοχεα αλφα (ppar) | |
| MX2009001711A (es) | Formulaciones de liberacion sostenida de topiramato. | |
| EA200870368A1 (ru) | Антибиотические композиции с модифицированным высвобождением и способ их получения | |
| CO6470887A2 (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona. | |
| ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
| PA8555401A1 (es) | Derivados de quinolina | |
| NO20073456L (no) | Omega-3 fettsyrer og dyslipidemisk middel for lipidbehandling | |
| AR062841A1 (es) | Tratamiento del dolor, diabetes, y trastornos del metabolismo de los lipidos | |
| CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
| BRPI0406883A (pt) | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
| AR034396A1 (es) | Compuestos 4-(1r-4-piperidilen)-4h-benzo[4,5]ciclohepta[1,2]-tiofeno-1-a y sus isomeros opticamente activos, un metodo para su sintesis y el uso de dichos compuestos para la manufactura de un medicamento | |
| AR040709A1 (es) | Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion | |
| MY147450A (en) | Pharmaceutical combination | |
| DE602005019043D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| PT1185253E (pt) | Forma de administracao oral para administracao de uma combinacao fixa de tramadol e diclofenac | |
| AR057946A1 (es) | Formulacion de zonisamida de liberacion sostenidda | |
| AR033957A1 (es) | Nuevos compuestos | |
| AR046454A1 (es) | Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceutica | |
| BRPI0507657A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
| UY29065A1 (es) | Derivados del ácido alcanoico arilcicloalquil-sustituidos, procedimientos para su preparación y su uso como productos farmacéuticos. | |
| ATE339202T1 (de) | Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs | |
| AR037496A1 (es) | Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| EA200500427A1 (ru) | Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |